Concepedia

Conrad Jacobs

CJ

8

Publications

2.1K

Citations

8

H-Index

1982

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

The Medical Oncology Centre of Rosebank

Ulsan College

The Maria Sklodowska-Curie National Research Institute of Oncology

Yonsei University

Conrad Jacobs is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, medicine, and cancer therapeutics.

Top concepts

Publications per year

1982–2024

8

Publications

8

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

, , +7

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez et al. · The Lancet Oncology · 2023 · 521 citations

, , +8

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

Fred Saad, Egils Vjaters, Neal D. Shore et al. · Journal of Clinical Oncology · 2024 · 102 citations · Full text

Lymphomas of the head and neck.

Anthony Po Wing Yuen, Conrad Jacobs · PubMed · 1999 · 78 citations

A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma

Mariko Mani, Rachna T. Shroff, Conrad Jacobs et al. · Journal of Clinical Oncology · 2008 · 24 citations

, , +15

Rows per page

1–5 of 8